Previous Close | 0.0700 |
Open | 0.0700 |
Bid | 0.0500 |
Ask | 0.1000 |
Strike | 2.00 |
Expire Date | 2024-10-18 |
Day's Range | 0.0700 - 0.0700 |
Contract Range | N/A |
Volume | |
Open Interest | 331 |
SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data from the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit, which will take place June 18–20, 2024 in Boston. Details of the presentation are as follows: Presentation Title:Empowering Peptide Self Administration with Needle-Free Smart CapsulesTrack: Pion
Four clinical device performance studies successfully demonstrate the NaviCap platform’s ability to deliver therapeutics directly to the colon under variable GI conditions and eating schedulesSAN DIEGO, May 20, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, presented a poster titled “Results of human device function studies for the NaviCap™ Targeted Oral Delivery Platform in healthy volunteers and patients with UC”
Explore key financial outcomes, strategic advancements, and expert insights from Biora Therapeutics' first quarter earnings discussion.